Tasigna (Nilotinib) Products Liability Litigation
The scientific causation theory in MDL-3006 involves the association of Nilotinib with vascular injuries, including atherosclerosis and peripheral arterial disease. FDA label updates acknowledge these risks, and scientific literature supports the hypothesis that Nilotinib's mechanism as a kinase inhibitor may promote vascular inflammation and plaque formation, leading to severe cardiovascular events. Expert testimony and medical studies underpin the legal allegations that Novartis failed to warn adequately about these risks.
36
Pending actions
39
Total actions filed
Active
Status
08/10/2021
Established
Filing deadline
No specific deadlines beyond standard federal MDL procedures are publicly available. The statutes of limitations for such claims generally range from 2 to 4 years, depending on jurisdiction and specific claim details.
Who qualifies
Plaintiffs generally must have used Tasigna (Nilotinib) and suffered injuries related to severe atherosclerotic or cardiovascular conditions. Specific exposure thresholds, such as dosage and duration, are not explicitly detailed in publicly available court documents. Plaintiffs are required to submit detailed medical and drug usage histories via plaintiff fact sheets, with a typical submission window of 60 days after docketing.
Products involved
- Tasigna
- Nilotinib
Alleged injuries
- Severe atherosclerotic injuries
- Peripheral arterial occlusive disease
- Cardiovascular events such as heart attack or stroke
Bellwether trials
The MDL-3006 Tasigna litigation is currently in active pre-trial phases with ongoing discovery and procedural motions. Recent court orders from March 2026 indicate procedural filings, but no specific bellwether trial dates or verdicts have been publicly announced. The trials are tentatively scheduled for late 2026 or early 2027, with settlement discussions ongoing.
Settlement landscape
No concrete settlement amounts or verdicts have been publicly disclosed as of March 2026. Industry estimates suggest potential payouts ranging from hundreds of millions to over a billion dollars, depending on case specifics and severity of injuries. Settlement discussions are ongoing, with some sources indicating active negotiations to resolve claims early to reduce trial burdens.
Lead counsel
- Raymond C. Silverman
- Robert E. Johnston
- Curtis Law Firm LLC
- The Lyon Firm
This page is generated from the official JPML pending-MDL report and public court records, refreshed monthly. It is provided for attorney reference and is not legal advice.
